Form 4: Adaptive Biotechnologies Executive Sells Shares
Insider Transaction (Form 4)
Francis Lo, Chief People Officer of Adaptive Biotechnologies Corp, sold 26,792 shares of common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 8,038 Common Stock at $8.46 ($68,001) on October 1, 2026; holds 228,905 after (Direct).
- Option exercise/conversion: acquired 9,377 Common Stock at $3.99 ($37,414) on October 1, 2026; holds 238,282 after (Direct).
- Option exercise/conversion: acquired 9,377 Common Stock at $8.12 ($76,141) on October 1, 2026; holds 247,659 after (Direct).
- Open-market sale: disposed of 8,094 Common Stock at $27.52 ($222,747) on October 1, 2026; holds 239,565 after (Direct).
- Open-market sale: disposed of 18,698 Common Stock at $28.61 ($534,950) on October 1, 2026; holds 220,867 after (Direct).
- Option exercise/conversion: disposed of 8,038 Stock Option (right to buy) on October 1, 2026; holds 16,075 after (Direct).
- Option exercise/conversion: disposed of 9,377 Stock Option (right to buy) on October 1, 2026; holds 56,259 after (Direct).
- Option exercise/conversion: disposed of 9,377 Stock Option (right to buy) on October 1, 2026; holds 93,765 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $757,697 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Francis Lo — Officer (Chief People Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 8,038 | $8 | $68.0K | 228,905 |
| 2026-10-01 | Option exercise/conversion | Common Stock | 9,377 | $4 | $37.4K | 238,282 |
| 2026-10-01 | Option exercise/conversion | Common Stock | 9,377 | $8 | $76.1K | 247,659 |
| 2026-10-01 | Open-market sale | Common Stock | 8,094 | $28 | $222.7K | 239,565 |
| 2026-10-01 | Open-market sale | Common Stock | 18,698 | $29 | $534.9K | 220,867 |
| 2026-10-01 | Option exercise/conversion | Stock Option (right to buy) | 8,038 | — | — | 16,075 |
| 2026-10-01 | Option exercise/conversion | Stock Option (right to buy) | 9,377 | — | — | 56,259 |
| 2026-10-01 | Option exercise/conversion | Stock Option (right to buy) | 9,377 | — | — | 93,765 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (8,038 shares) |
| 2026-10-01 | Option exercise/conversion (9,377 shares) |
| 2026-10-01 | Option exercise/conversion (9,377 shares) |
| 2026-10-01 | Open-market sale (8,094 shares) |
| 2026-10-01 | Open-market sale (18,698 shares) |
| 2026-10-01 | Option exercise/conversion (8,038 shares) |
| 2026-10-01 | Option exercise/conversion (9,377 shares) |
| 2026-10-01 | Option exercise/conversion (9,377 shares) |
Keywords
insider transaction, Form 4, ADPT, Adaptive Biotechnologies Corp, bearish, Francis Lo
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.